507 related articles for article (PubMed ID: 36263032)
1. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Hajibeygi R; Shool S; Sodeifian F; Klegeris A; McElhinney A; Tavirani MR; Sayehmiri F
Front Immunol; 2022; 13():997240. PubMed ID: 36263032
[TBL] [Abstract][Full Text] [Related]
2. Kynurenine pathway in Parkinson's disease-An update.
Venkatesan D; Iyer M; Narayanasamy A; Siva K; Vellingiri B
eNeurologicalSci; 2020 Dec; 21():100270. PubMed ID: 33134567
[TBL] [Abstract][Full Text] [Related]
3. Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is Different in Parkinson's and Alzheimer's Diseases.
Oxenkrug G; van der Hart M; Roeser J; Summergrad P
Endocrinol Diabetes Metab J; 2017 Nov; 1(4):. PubMed ID: 29292800
[TBL] [Abstract][Full Text] [Related]
4. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
[TBL] [Abstract][Full Text] [Related]
5. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
6. Kynurenine and its metabolites in Alzheimer's disease patients.
Gulaj E; Pawlak K; Bien B; Pawlak D
Adv Med Sci; 2010; 55(2):204-11. PubMed ID: 20639188
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.
Mazarei G; Leavitt BR
J Huntingtons Dis; 2015; 4(2):109-18. PubMed ID: 26397892
[TBL] [Abstract][Full Text] [Related]
8. Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy.
Ryan KM; Allers KA; McLoughlin DM; Harkin A
Brain Behav Immun; 2020 Jan; 83():153-162. PubMed ID: 31606477
[TBL] [Abstract][Full Text] [Related]
9. Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls.
Schwarz MJ; Guillemin GJ; Teipel SJ; Buerger K; Hampel H
Eur Arch Psychiatry Clin Neurosci; 2013 Jun; 263(4):345-52. PubMed ID: 23192697
[TBL] [Abstract][Full Text] [Related]
10. Altered kynurenine pathway metabolites in serum of chronic migraine patients.
Curto M; Lionetto L; Negro A; Capi M; Fazio F; Giamberardino MA; Simmaco M; Nicoletti F; Martelletti P
J Headache Pain; 2015; 17():47. PubMed ID: 27130315
[TBL] [Abstract][Full Text] [Related]
11. Age- and disease-specific changes of the kynurenine pathway in Parkinson's and Alzheimer's disease.
Sorgdrager FJH; Vermeiren Y; Van Faassen M; van der Ley C; Nollen EAA; Kema IP; De Deyn PP
J Neurochem; 2019 Dec; 151(5):656-668. PubMed ID: 31376341
[TBL] [Abstract][Full Text] [Related]
12. The Involvement of Kynurenine Pathway in Neurodegenerative Diseases.
Martins LB; Silveira ALM; Teixeira AL
Curr Neuropharmacol; 2023; 21(2):260-272. PubMed ID: 36154606
[TBL] [Abstract][Full Text] [Related]
13. Altered kynurenine pathway metabolism and association with disease activity in patients with systemic lupus.
Eryavuz Onmaz D; Tezcan D; Yilmaz S; Onmaz M; Unlu A
Amino Acids; 2023 Dec; 55(12):1937-1947. PubMed ID: 37925676
[TBL] [Abstract][Full Text] [Related]
14. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
Campesan S; Green EW; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
Curr Biol; 2011 Jun; 21(11):961-6. PubMed ID: 21636279
[TBL] [Abstract][Full Text] [Related]
15. Altered serum levels of kynurenine metabolites in patients affected by cluster headache.
Curto M; Lionetto L; Negro A; Capi M; Perugino F; Fazio F; Giamberardino MA; Simmaco M; Nicoletti F; Martelletti P
J Headache Pain; 2015; 17(1):27. PubMed ID: 27000870
[TBL] [Abstract][Full Text] [Related]
16. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
[TBL] [Abstract][Full Text] [Related]
17. Effect of Kynurenic Acid on Pupae Viability of Drosophila melanogaster cinnabar and cardinal Eye Color Mutants with Altered Tryptophan-Kynurenine Metabolism.
Navrotskaya V; Wnorowski A; Turski W; Oxenkrug G
Neurotox Res; 2018 Aug; 34(2):324-331. PubMed ID: 29619629
[TBL] [Abstract][Full Text] [Related]
18. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
19. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
Breda C; Sathyasaikumar KV; Sograte Idrissi S; Notarangelo FM; Estranero JG; Moore GG; Green EW; Kyriacou CP; Schwarcz R; Giorgini F
Proc Natl Acad Sci U S A; 2016 May; 113(19):5435-40. PubMed ID: 27114543
[TBL] [Abstract][Full Text] [Related]
20. Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk A; Urbanska EM
CNS Neurosci Ther; 2022 Jan; 28(1):19-35. PubMed ID: 34862742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]